Abstract:Objective To investigate the expression level and potential mechanism of hypoxia-inducible factor 1 alpha (HIF-1 alpha) in patients with myelodysplastic syndromes (MDS). Methods Immunohistochemistry (IHC) techniques were used to examine the protein expression of HIF-1 alpha in paraffin-embedded myeloid tissues from 82 patients with MDS and 33 controls (patients with lymphoma that is not invading myeloid tissues). In addition, the associations between the protein expression of HIF-1 alpha and clinical parameters were examined. To further investigate the significance of HIF-1 alpha expression in MDS patients, the researchers not only extracted the data about HIF-1 alpha expression from MDS-related microarrays but also analyzed the correlation between the level of HIF-1 alpha expression and MDS. The microRNA (miRNA) targeting HIF-1 alpha was predicted and verified with a dual luciferase experiment. Results Immunohistochemistry revealed that the positive expression rate of HIF-1 alpha in the bone marrow of patients with MDS was 90.24%. This rate was remarkably higher than that of the controls (72.73%) and was statistically significant (P < .05), which indicated that HIF-1 alpha was upregulated in the myeloid tissues of MDS patients. For the GSE2779, GSE18366, GSE41130, and GSE61853 microarrays, the average expression of HIF-1 alpha in MDS patients was higher than in the controls. Particularly for the GSE18366 microarray, HIF-1 alpha expression was considerably higher in MDS patients than in the controls (P < .05). It was predicted that miR-93-5p had a site for binding with HIF-1 alpha, and a dual luciferase experiment confirmed that miR-93-5p could bind with HIF-1 alpha. Conclusion The upregulated expression of HIF-1 alpha was examined in the myeloid tissues of MDS patients. The presence of HIF-1 alpha (+) suggested an unsatisfactory prognosis for patients, which could assist in the diagnosis of MDS. In addition, miR-93-5p could bind to HIF-1 alpha by targeting, showing its potential to be the target of HIF-1 alpha in MDS.

The Association Between Expression of Hypoxia Inducible Factor-1Α and Multi-Drug Resistance of Acute Myeloid Leukemia

Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

Expression of the Hypoxia-Inducible Factors in the AML and MDS: is Not Associated with the Von Hippel-Lindau Gene

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

Prognostic Impact of MYH9 Expression on Patients with Acute Myeloid Leukemia

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

MiR-425 Expression Profiling in Acute Myeloid Leukemia Might Guide the Treatment Choice Between Allogeneic Transplantation and Chemotherapy

HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia

HIF-1α and GLUT1 Gene Expression is Associated with Chemoresistance of Acute Myeloid Leukemia

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

Survival impact of hypoxia-inducible factor-1 alpha (HIF-1α) in Nucleophosmin1 mutated acute myeloid leukemia

Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML

Abnormal Expression of Hematopoietic Regulatory Factors in Newly Diagnosed Patients with Acute Myeloid Leukemia

Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia

High expression of miR‐338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy

High Expression of Microrna-500 is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.